Capital Research Global Investors Trims Johnson & Johnson Stake

Institutional investor reduces holding in healthcare giant by 11%

Mar. 11, 2026 at 9:10am

Got story updates? Submit your updates here. ›

Capital Research Global Investors, a major institutional investor, has reduced its stake in Johnson & Johnson (NYSE: JNJ) by 11% in the third quarter, according to a recent SEC filing. The fund now owns approximately 3 million shares of the healthcare company, valued at nearly $559 million.

Why it matters

Johnson & Johnson is one of the world's largest and most influential pharmaceutical and medical device companies, so changes in major investor holdings can signal broader market sentiment and potential shifts in the company's strategic direction.

The details

According to the filing, Capital Research Global Investors sold 372,720 shares of Johnson & Johnson stock during the third quarter. The fund now owns around 3 million shares, or 0.13% of the company's total outstanding shares. The sale reduced Capital Research's overall stake in JNJ by 11%.

  • The share sale occurred in the third quarter of the year.

The players

Capital Research Global Investors

A major institutional investment management firm that owns stakes in many large public companies.

Johnson & Johnson

A multinational healthcare company that develops, manufactures and markets pharmaceutical, medical device, and consumer health products.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Capital Research's Johnson & Johnson holdings, while relatively small, could signal a broader shift in investor sentiment around the healthcare giant as it navigates industry challenges and evolving market dynamics.